Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

New Xolair® Treats Severe Chronic Rhinosinusitis with Nasal Polyps

Novartis has discovered a new Xolair® indication for the treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for adults.

Xolair® (omalizumab), is the first discovered treatment option for CRSwNP which specifically targets and blocks the growth of Immunoglobulin E (IgE), which is supposed to be a key driver in the inflammatory pathway of the disease.

Xolair® (omalizumab) discovered has the ability to block immunoglobulin E. Once approved it can provide a new treatment option for patients for whom intranasal corticosteroids do not generate adequate disease control. Moreover, it also shows significant symptoms in patients thereby improving the patient’s quality of life.

European Commission (EC) has approved Xolair® (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) occurs in adults by affecting inflammation of the nose and paranasal sinuses which normally blocks the airflow in the nose with the existence of nasal polyps.

Patients with severe chronic rhinosinusitis with nasal polyps can be often seen suffering with symptoms such as nasal congestion, facial pain, loss of sense of smell and taste, difficulty in breathing and sleep problems affecting their quality of life.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024